Le Lézard
Classified in: Health, Science and technology

Kalderos Files Amicus Brief in Arkansas Contract Pharmacy Litigation


CHICAGO, April 18, 2024 /PRNewswire/ -- Data infrastructure and analytics company Kalderos, Inc., today announced that on Tuesday, April 16, it asked the Eighth Circuit for leave to file an amicus brief in support of Pharmaceutical Research and Manufacturers of America's (PhRMA's) petition for rehearing in the Arkansas contract pharmacy litigation.

Click to Read Kalderos Motion

Click to Read Kalderos Amicus Brief

Kalderos asked the U.S. Court of Appeals for the Eighth Circuit for permission to file an amicus brief in support of PhRMA's petition for rehearing en banc of the court's decision holding that Arkansas Act 1103 is not preempted by federal law.

Arkansas Act 1103 prohibits drug manufacturers from denying access to federal 340B drug pricing by Arkansas-based contract pharmacies receiving drugs purchased pursuant to an arrangement with a covered entity under the 340B Program.

Kalderos submitted this brief in support of the petition for rehearing because the decision upsets the existing regulatory structure of the 340B Program adopted by Congress. As explained by Plaintiff-Appellant, Act 1103 conflicts with the federal scheme by undercutting the Health Resources Services Administration's regulatory authority over the program.

To operate as intended for all stakeholders, Kalderos believes the 340B Program requires the free flow of data necessary to ensure that the federal 340B Program's requirements are followed by all stakeholders.

The company has developed an equitable, easy-to-use technology platform designed to implement the drug-discount program on behalf of covered entities and participating drug manufacturers.  

Its platform facilitates the operation of the 340B Program within the federal regulatory framework by (1) ensuring that covered entities receive the discounted price required by statute, and (2) helping participants identify and reduce prohibited diversion and duplicate discounts.

About Kalderos 
Kalderos is a data infrastructure and analytics company that created the world's first Drug Discount Management platform, simplifying drug discount program compliance for all stakeholders. The platform applies sophisticated data models and machine learning to identify and resolve noncompliance, with collaboration-oriented solutions built for both drug manufacturers and covered entities. Based in?Chicago, Kalderos was founded in 2016 by a team dedicated to reducing inefficiencies in the U.S. healthcare system, empowering everyone to focus on the health of people. More information can be found at?www.kalderos.com

Media contact:

Philip Anast 
Amendola (for Kalderos) 
[email protected] 
312-576-6990 

SOURCE Kalderos


These press releases may also interest you

at 16:20
Butterfly Network, Inc. ("Butterfly" or the "Company"), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced financial results for the first quarter ended March 31, 2024, and...

at 16:20
Mirum Pharmaceuticals, Inc. today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress....

at 16:15
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024. "We are pleased to announce another strong quarter of growth from our four approved therapies,...

at 16:10
Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March...

at 16:10
Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast...

at 16:10
Prothena Corporation plc , a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on...



News published on and distributed by: